Ingunn Munch Lindvig
Algemeen Adviseur bij BIOINVENT INTERNATIONAL AB
Profiel
Ingunn Munch Lindvig is currently the Senior Vice President-Regulatory Affairs at BioInvent International AB since 2023.
Previously, she worked as the Head-Regulatory Affairs at Nordic Nanovector ASA and as the Vice President & Head-Regulatory Affairs at Circio Holding ASA. Dr. Lindvig holds a doctorate degree from the University of Oslo.
Actieve functies van Ingunn Munch Lindvig
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOINVENT INTERNATIONAL AB | Algemeen Adviseur | 12-06-2023 |
Eerdere bekende functies van Ingunn Munch Lindvig
| Bedrijven | Functie | Einde |
|---|---|---|
| THOR MEDICAL | Algemeen Adviseur | - |
| CIRCIO HOLDING ASA | Algemeen Adviseur | - |
Opleiding van Ingunn Munch Lindvig
| University of Oslo | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CIRCIO HOLDING ASA | Health Technology |
| BIOINVENT INTERNATIONAL AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
